Precision BioSciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Precision BioSciences, Inc.
During Q2, biopharma merger and acquisition value reached $25.4bn and drew in $27.3bn in potential deal value from alliances. Device company M&A values reached $2.7bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $534.3m.
Novartis is once again looking to be a pioneer in cell and gene therapy, though this time is selecting a potentially less complex administration method.
The company provided Phase I/IIa data for allogeneic CAR-T PBCAR0191 showing a high response rate and signs of durability in aggressive NHL patients relapsing after autologous CAR-T.
The company aims to file for desmoid tumors in the second half of 2022, but it has more than half a dozen combination programs with BCMA-targeting therapies in multiple myeloma.
- Gene Therapy, Cell Therapy
Drug Discovery Tools
- Other Names / Subsidiaries
- Elo Life Systems
- Precision PlantSciences